Mazor signed commercial agreements with Medtronic last May, giving Medtronic exclusive distribution rights for new Mazor spine products in exchange for roughly $52 million in total potential investment.
In the first stage of the investment, Medtronic paid $11.9 million for 4 percent of Mazor’s shares.
Mazor’s launch of the new Mazor X System will trigger Medtronic’s second-stage investment of up to $20 million.
The third stage of investment, also reaching a potential of $20 million, is contingent upon several terms, including the establishment of a global distribution agreement between the two companies.
More articles on supply chain:
GE stakes claim on cell therapy market with Biosafe acquisition
10 costliest medical conditions
FDA Commissioner: US needs improved system to track medical device issues
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
